Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race

Ganesh M. Babulal, Sanne Franzen, Erin L. Abner, Jade Emily Smith, Esther van den Berg, Monica Rivera Mindt, Rozermarijn Lidewij van Bruchem-Visser, Lon S. Schneider, Niels D. Prins, Janne M. Papma

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish
Pages (from-to)867-868
Number of pages2
JournalAlzheimer's and Dementia
Volume18
Issue number4
DOIs
StatePublished - Apr 2022

Bibliographical note

Funding Information:
SF and JMP report a grant from The Netherlands Organisation for Health Research and Development/Alzheimer's Nederland (ZonMw Memorabel; grant number 733050834). JES reports a personal James B. Reynolds scholarship for foreign study. LSS reports a grant from NIH (P30 AG066530). GMB reports grants from NIH/NIA (R01AG068183, R01AG067428, A2021142S) and the BrightFocus Foundation (A2021142S). MRM is supported by grants from the NIA/NIH (R13 AG071313‐01, R01AG065110‐01A1, NIH/NIA 5U19AG024904‐14, NIH/NIA R01AG066471‐01A1), NIH/NIMH (U24MH100931‐03), NIH/NIA (5R24AG065163), National Science Foundation, the Genentech Health Equity 2020 Fund (G‐89294), and the Alzheimer's Association (AARGD‐16‐446038).

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race'. Together they form a unique fingerprint.

Cite this